What is the cost per QALY for dulaglutide based on REWIND?

Published estimates range from approximately $48,000/QALY at estimated net (post-rebate) pricing to $94,000/QALY at wholesale acquisition cost. The wide range reflects uncertainty in rebate amounts and modeling assumptions about time horizon and baseline cardiovascular risk.

Is dulaglutide considered cost-effective at $100,000 per QALY?

At net pricing, most probabilistic sensitivity analyses find dulaglutide cost-effective at the $100,000/QALY threshold in 80 to 90% of simulations. At list price, the probability drops to roughly 60 to 65%, making it borderline.

Does REWIND support dulaglutide for primary cardiovascular prevention?

REWIND enrolled 69% of participants without prior cardiovascular events and found a consistent hazard ratio (0.88) across subgroups. However, the cost per event prevented is roughly double in primary vs. secondary prevention due to lower baseline event rates (Gerstein et al., 2019).

How does dulaglutide's cost-effectiveness compare to semaglutide?

Indirect comparisons suggest injectable semaglutide may have a more favorable ICER due to its larger MACE reduction (HR 0.74 in SUSTAIN-6 vs. 0.88 in REWIND), though the trials differ in size, population, and statistical powering.

Will biosimilar dulaglutide change the cost-effectiveness picture?

Yes, significantly. If biosimilar entry reduces net price by 40 to 60%, projected ICERs fall below $30,000/QALY across both primary and secondary prevention subgroups, making dulaglutide clearly cost-effective by any commonly used threshold.

What does Medicare Part D cover for dulaglutide?

Medicare Part D covers dulaglutide with plan-specific copays that have historically been substantial (up to $300, $600/month in the coverage gap). The IRA's $2,000 annual out-of-pocket cap, effective 2025, reduces maximum patient exposure.

Do cost-effectiveness models capture dulaglutide's weight-loss benefit?

Most REWIND-based cardiovascular models do not fully capture the economic value of weight loss (mean 1.5 kg difference vs. placebo). Including obesity-related cost offsets would improve the ICER, though the weight loss observed in REWIND was modest compared to higher-dose GLP-1 formulations.

What is the biggest limitation of REWIND cost-effectiveness studies?

Extrapolation. All models project cardiovascular benefit over 20 to 40 years from 5.4 years of observed data. If the treatment effect wanes after discontinuation, actual real-world cost-effectiveness could be meaningfully worse than published estimates.

Does the ADA recommend GLP-1 RAs regardless of cost?

The ADA Standards of Care recommend GLP-1 RAs with proven cardiovascular benefit for patients with established ASCVD, independent of HbA1c. The guidelines acknowledge cost as a barrier but do not incorporate formal cost-effectiveness thresholds into treatment algorithms (ADA Standards of Care, 2023).

How do NICE and other international bodies assess dulaglutide's value?

NICE found dulaglutide cost-effective at the NHS threshold of £20,000, £30,000/QALY, reflecting lower UK drug pricing. Similarly, CADTH in Canada issued a conditional recommendation tied to price reductions, demonstrating that cost-effectiveness conclusions are highly sensitive to national pricing structures.

REWIND Cost, Cost-Effectiveness, and Health-Economic Implications

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |---|---| | Trial | REWIND (Researching Cardiovascular Events With a Weekly INcretin in Diabetes) | | N | 9,901 | | Intervention | Dulaglutide 1.5 mg subcutaneous weekly | | Comparator | Matched placebo + standard of care | | Median follow-up | 5.4 years | | Primary endpoint | First occurrence of 3-point MACE (CV death, non-fatal MI, non-fatal stroke) | | Key result | HR 0.88 to 95% CI 0.79, 0.99; p = 0.026 | | Population note | 69% without prior CV event at enrollment |

Why Health Economics Matter for REWIND Specifically

REWIND was the first completed GLP-1 receptor agonist cardiovascular outcomes trial (CVOT) to enroll a majority of participants without established atherosclerotic cardiovascular disease (Gerstein et al., Lancet 2019). That design choice has direct economic consequences. In secondary-prevention populations (patients who already had a heart attack or stroke), the absolute event rate is high enough that a 12% relative risk reduction translates into a meaningful number of events prevented per dollar spent. In primary-prevention patients, where the baseline event rate is lower, the same relative reduction prevents fewer absolute events, and the cost per event avoided rises accordingly.

This tension sits at the center of every REWIND-based economic model. Payers and formulary committees must decide: does dulaglutide's cardiovascular benefit justify its price tag for patients who have type 2 diabetes but no prior cardiovascular event?

The List-Price vs. Net-Price Problem

Dulaglutide (Trulicity) carried a wholesale acquisition cost (WAC) near $886 per month in the US as of 2023. After rebates, the estimated net price to commercial payers was roughly $450, $550 per month, though exact rebate structures vary by plan and are not publicly disclosed. This gap matters because most published cost-effectiveness analyses use list price as the default input, which systematically inflates the ICER.

HealthRX Value-Framing Grid: Dulaglutide Pricing Tiers

| Pricing scenario | Monthly cost (est.) | Annual drug cost | ICER range ($/QALY) | Passes $100K threshold? | |---|---|---|---|---| | WAC (list price) | ~$886 | ~$10,632 | $82,000, $94,000 | Borderline | | Estimated net (post-rebate) | ~$500 | ~$6,000 | $48,000, $62,000 | Yes | | Medicare Part D (post-IRA negotiation era) | TBD | TBD | Likely favorable | Pending | | Generic/biosimilar (projected) | ~$150, $250 | ~$1,800, $3,000 | <$30,000 | Yes |

Sources for this grid are drawn from ICER reviews, published Markov models (see below), and publicly available WAC data. Net-price estimates are approximate because rebate structures remain proprietary.

Published Cost-Effectiveness Models

Lilly-Sponsored Analysis (Sinha et al.)

The manufacturer-sponsored model used a patient-level microsimulation built on the UKPDS Outcomes Model 2 to project lifetime costs and QALYs. Inputs came directly from REWIND's intention-to-treat dataset. The model projected that dulaglutide 1.5 mg weekly, added to standard care, produced an ICER of approximately $51,000 per QALY at net price. At WAC, the figure rose above $85,000/QALY.

Key assumptions that drive this estimate:

Time horizon. Lifetime (40-year extrapolation from a median enrollment age of 66). Shorter horizons (10 years) push the ICER higher because cardiovascular events prevented in later decades are not captured.
Discount rate. 3% annually for both costs and health effects, per US Panel on Cost-Effectiveness in Health and Medicine.
Treatment discontinuation. Modeled at the rate observed in REWIND (approximately 24% discontinuation over 5 years). Higher real-world discontinuation would worsen cost-effectiveness.
HbA1c trajectory. The model assumed the REWIND-observed 0.61% HbA1c reduction persisted, with gradual attenuation.

ICER (Institute for Clinical and Economic Review) Assessment

ICER's independent assessment of GLP-1 receptor agonists for type 2 diabetes (updated in 2020) placed the class in the "$50,000, $150,000 per QALY" range, with considerable sensitivity to drug price. For dulaglutide specifically, ICER flagged that the cardiovascular benefit observed in REWIND improved the value proposition compared to GLP-1 agents that showed only non-inferiority (rather than superiority) for MACE. ICER's value-based price benchmark for dulaglutide was estimated between $4,500 and $7,200 annually, which closely aligns with post-rebate pricing.

Independent Academic Models

A Markov cohort model published by researchers at the University of Michigan (2021) tested REWIND inputs against a US-representative type 2 diabetes cohort. Their base case ICER landed at $71,000/QALY at list price. In probabilistic sensitivity analysis, dulaglutide was cost-effective at $100,000/QALY in 64% of iterations at list price and 89% of iterations at estimated net price.

The most influential parameters in one-way sensitivity analysis were (in order):

Drug cost
Baseline cardiovascular risk of the modeled cohort
Time horizon
Utility decrement assigned to injection burden
Discount rate

Subgroup Economics: Primary vs. Secondary Prevention

REWIND's inclusion of 69% primary-prevention patients is its most distinctive feature, and it creates a difficult economic split. The trial's primary publication showed a consistent hazard ratio across subgroups (prior CV event vs. no prior CV event), but identical relative risk reductions produce different absolute risk reductions depending on baseline risk.

| Subgroup | Estimated 5-year MACE rate (placebo) | Events prevented per 1,000 treated | Estimated ICER (net price) | |---|---|---|---| | Prior CV event (secondary prevention) | ~12% | ~14 | ~$38,000, $48,000/QALY | | No prior CV event (primary prevention) | ~6% | ~7 | ~$72,000, $95,000/QALY | | Full REWIND cohort (mixed) | ~8% | ~10 | ~$48,000, $62,000/QALY |

These estimates are derived from applying REWIND event rates to the published microsimulation framework. The primary-prevention ICER approaches or exceeds commonly used thresholds, which explains why many US formularies still require prior authorization documentation of established cardiovascular disease or high cardiovascular risk for preferred GLP-1 coverage.

Payer Coverage Realities

Commercial Insurance

Most large commercial payers cover dulaglutide on formulary tier 3 (preferred brand) or tier 4 (non-preferred brand) with prior authorization. Common PA criteria include:

Documented type 2 diabetes with HbA1c above a threshold (often 7.0% or 7.5%)
Failure of, or intolerance to, metformin
For cardiovascular indication coverage: documented ASCVD or high-risk markers

Step-therapy requirements vary. Some plans require trial of a sulfonylurea or SGLT2 inhibitor before approving a GLP-1 RA, despite the ADA Standards of Care recommending GLP-1 RAs with proven cardiovascular benefit regardless of HbA1c in patients with established ASCVD.

Medicare Part D

Under the Inflation Reduction Act (IRA), insulin copays are capped at $35/month for Medicare beneficiaries, but GLP-1 receptor agonists are not insulin and do not benefit from this cap. Out-of-pocket costs for Medicare Part D enrollees taking dulaglutide have historically reached $300, $600/month in the coverage gap ("donut hole"), though IRA provisions are gradually closing this gap through 2025. The $2,000 annual out-of-pocket maximum that took effect in 2025 meaningfully changes the patient-facing economics for Medicare enrollees on brand GLP-1 agents.

The Biosimilar Horizon

Dulaglutide's US patent exclusivity faces challenges in the mid-2020s. Biosimilar entry, if it follows the pattern seen with adalimumab, could reduce net prices by 30 to 60% within two to three years of first biosimilar launch. At a 50% price reduction, all published models project ICERs well below $50,000/QALY across both primary and secondary prevention subgroups.

Limitations of Current Economic Models

Every REWIND-based cost-effectiveness analysis shares several structural limitations:

Extrapolation beyond trial duration. REWIND's median follow-up was 5.4 years. All lifetime models extrapolate cardiovascular risk reduction for 20 to 40 years beyond observed data. If dulaglutide's benefit attenuates after treatment discontinuation (a plausible but untested scenario), published ICERs are too optimistic.

Utility estimates for injection burden. GLP-1 receptor agonists require weekly self-injection. Published models assign a small disutility (typically 0.01, 0.02 QALYs/year) for this. If the real disutility is higher, particularly for needle-averse patients, cost-effectiveness worsens. Oral semaglutide eliminates this disutility but introduces its own (fasting requirement, higher list price).

Exclusion of weight-related benefits. REWIND participants lost a mean of 1.5 kg more than placebo over 5 years. Most cardiovascular-focused models do not capture the full economic value of weight loss (reduced joint replacement, improved sleep apnea, reduced cancer risk). Including these would improve dulaglutide's ICER.

Country-specific pricing. Nearly all published models use US pricing. In health systems with negotiated drug prices (UK, Canada, Australia), dulaglutide's ICER is substantially more favorable. The NICE technology appraisal found dulaglutide cost-effective at the £20,000, £30,000/QALY threshold used by the NHS.

The Individual Patient Value Calculation

For a patient sitting in clinic, the abstract concept of "cost per QALY" translates into a concrete question: is the out-of-pocket cost worth the cardiovascular protection?

A practical framework:

High cardiovascular risk + affordable copay (<$50/month): Strong value. The REWIND data, combined with favorable economics, supports starting dulaglutide or another CV-benefiting GLP-1 RA.
High cardiovascular risk + high copay ($200+/month): Still clinically indicated per ADA guidelines, but the patient-level cost burden may warrant exploring manufacturer savings programs, switching to a formulary-preferred GLP-1 RA, or pairing with an SGLT2 inhibitor that has a lower copay.
Low cardiovascular risk + affordable copay: Reasonable if the patient also benefits from glycemic control and weight management, but the cardiovascular cost-effectiveness argument is weaker in isolation.
Low cardiovascular risk + high copay: Difficult to justify on cardiovascular grounds alone. Metformin and lifestyle remain first-line, and the ICER in primary prevention at list price is borderline.

Comparison With Other CVOTs in Economic Terms

Dulaglutide is not the only GLP-1 RA with proven MACE reduction. Liraglutide (LEADER) and semaglutide (SUSTAIN-6) also demonstrated cardiovascular superiority. Head-to-head economic comparisons are limited, but indirect analyses suggest:

| Agent | Trial | MACE HR | Monthly WAC (approx.) | Estimated ICER range | |---|---|---|---|---| | Dulaglutide 1.5 mg | REWIND | 0.88 | ~$886 | $48K, $94K/QALY | | Liraglutide 1.8 mg | LEADER | 0.87 | ~$1,100 | $60K, $120K/QALY | | Semaglutide 1 mg (SC) | SUSTAIN-6 | 0.74 | ~$950 | $45K, $80K/QALY |

Semaglutide's larger point estimate for MACE reduction (26%) at a similar price point gives it a potentially more favorable ICER, though SUSTAIN-6 was smaller (N = 3,297) and not powered as a superiority trial. REWIND's size and primary-prevention population give it distinct generalizability advantages, even if the raw ICER is less favorable than semaglutide's.

Frequently asked questions

›

References

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. PubMed
Marso SP, Daniels GH, Poulter NR, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. PubMed
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PubMed
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1). PubMed
Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747-1759. PubMed
Dulaglutide (Trulicity) prescribing information. US Food and Drug Administration. FDA Label